targetprint™ (Agendia BV)
90
Structured Review
Agendia BV
targetprint™
Targetprint™, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+gene-expression+test/targetprint/pmc04389676-132-0-1
Average 90 stars, based on 1 article reviews
Targetprint™, supplied by Agendia BV, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray-based+gene-expression+test/targetprint/pmc04389676-132-0-1
Average 90 stars, based on 1 article reviews
targetprint™ - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Diagnostic Assay:Article Title: Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands Article Snippet: The article aims to understand the institutionalisation process of markets for innovative products.. To pursue this study of market formation, we analysed the introduction of innovative personalised medicines products: Herceptin® (trastuzumab) for breast cancer and Tarceva® (erlotinib) for lung cancer, which were introduced successively in the Netherlands between 2000 and 2012.. We apply the technological innovation system (TIS) approach to understand the development, implementation and diffusion of new markets, including new roles for users and producers, new forms of regulation and novel user practices regarding innovative health technologies. Gene Expression:Article Title: Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer Article Snippet: .. We further compared Article Title: Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Article Snippet: .. HER2 status was defined as negative in both cohorts if not overexpressed (score 2) and not amplified (ERBB2 6 copies per nucleus and/or ERBB2/CEP17 ratio < 2.0), and also in the I-SPY2 trial only, if ERBB2 gene expression was not elevated ( Article Title: Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy Article Snippet: .. HER2 status was defined as negative in both cohorts if not overexpressed (score ≤ 2) and not amplified ( ERBB2 ≤ 6 copies per nucleus and/or ERBB2 /CEP17 ratio < 2.0), and also in the I-SPY2 trial only, if ERBB2 gene expression was not elevated ( Article Title: Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer Article Snippet: IHC remains the method of choice when testing for HER2 as well as for determining hormone receptor status, e.g., with the HercepTest (Daco), Insight Dx Mammostrat Plus (Clarient Diagnostic) or PATHWAY (Ventana Medical Systems) [ ]. .. Other methods rely on testing gene copy numbers using FISH, e.g., PathVysion Her-2 DNA Probe Kit (Abbott Molecular) [ ], CISH, e.g., Her2 CISH pharmDx kit (Dako) or by Gene Expression Tests, e.g., Immunohistochemistry:Article Title: Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer Article Snippet: .. We further compared Microarray:Article Title: Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint Article Snippet: .. Until early 2016, the Agendia Breast Cancer Suite also included a separate single-gene microarray for the estrogen receptor (ER), progesterone receptor (PR), and HER2 receptor, namely Amplification:Article Title: Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. Article Snippet: .. HER2 status was defined as negative in both cohorts if not overexpressed (score 2) and not amplified (ERBB2 6 copies per nucleus and/or ERBB2/CEP17 ratio < 2.0), and also in the I-SPY2 trial only, if ERBB2 gene expression was not elevated ( Article Title: Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy Article Snippet: .. HER2 status was defined as negative in both cohorts if not overexpressed (score ≤ 2) and not amplified ( ERBB2 ≤ 6 copies per nucleus and/or ERBB2 /CEP17 ratio < 2.0), and also in the I-SPY2 trial only, if ERBB2 gene expression was not elevated ( other:Article Title: 21-Gene recurrence score testing among Medicare beneficiaries with breast cancer in 2010-2013. Article Snippet: The distribution of Table 1 Claims for 21-gene and 70-gene breast cancer tests among Medicare beneficiaries in 2010 and 2013 Year 2010 2011 2012 2013 Total Percent change 21-gene RS test 10,988 12,976 13,392 13,517 50,873 23.0 Mean payments $3,323 $3,302 $3,324 $3,296 $3,311 -0.8 Total payments $36,508,894 $42,849,866 $44,513,830 $44,545,463 $168,418,052 22.0 Article Title: Genomic profiling of breast cancer in African-American women using MammaPrint. Article Snippet: Breast cancer in African-American females (AAF) has a less favorable outcome than that in Caucasians.. More information is needed regarding its biology.. We evaluated gene expression in tumors from AAF presenting with early stage or locally advanced breast cancer using MammaPrint , BluePrint (molecular subtype) and TargetPrint [estrogen receptor (ER), progesterone receptor, and Human Epidermal Growth Factor Receptor 2 (HER2) mRNA levels]. Fluorescence In Situ Hybridization:Article Title: Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer Article Snippet: IHC remains the method of choice when testing for HER2 as well as for determining hormone receptor status, e.g., with the HercepTest (Daco), Insight Dx Mammostrat Plus (Clarient Diagnostic) or PATHWAY (Ventana Medical Systems) [ ]. .. Other methods rely on testing gene copy numbers using FISH, e.g., PathVysion Her-2 DNA Probe Kit (Abbott Molecular) [ ], CISH, e.g., Her2 CISH pharmDx kit (Dako) or by Gene Expression Tests, e.g., Chromogenic In Situ Hybridization:Article Title: Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer Article Snippet: IHC remains the method of choice when testing for HER2 as well as for determining hormone receptor status, e.g., with the HercepTest (Daco), Insight Dx Mammostrat Plus (Clarient Diagnostic) or PATHWAY (Ventana Medical Systems) [ ]. .. Other methods rely on testing gene copy numbers using FISH, e.g., PathVysion Her-2 DNA Probe Kit (Abbott Molecular) [ ], CISH, e.g., Her2 CISH pharmDx kit (Dako) or by Gene Expression Tests, e.g., |